Abstract:Purpose:Clear cell renal cell carcinoma (ccRCC) is the most common pathology type in kidney cancer. However, the prognosis of advanced ccRCC is unsatisfactory. Thus, early diagnosis becomes one of the most important research priorities of ccRCC. However, currently available studies about ccRCC lack urine-related further studies. In this study, we applied proteomics to search urinary biomarkers to assist early diagnosis of ccRCC. In addition, we constructed a prognostic model to assist judge patients' prognosis.Materials and methods:Urine which was used to perform 4D label-free quantitative proteomics was collected from 12 ccRCC patients and 11 non-tumor patients with no urinary system diseases. The urine of 12 patients with ccRCC confirmed by pathological examination after surgery was collected before operatoin. Bioinformatics analysis was used to describe the urinary proteomics landscape of these patients with ccRCC. The top ten proteins with the highest expression content were selected as the basis for subsequent validation. Urine from 46 ccRCC patients and 45 control patients were collected to use for verification by enzyme linked immunosorbent assay (ELISA). In order to assess the prognostic value of urine proteomics, a prognostic model was constructed by COX regression analysis on the intersection of RNA-sequencing data in The Cancer Genome Atlas (TCGA) database and our urine proteomic data.Results:133 proteins differentially expressed in the urinary samples were found and 85 proteins (Fold Change, FC>1.5) were identified up-regulated while 48 down-regulated (FC<0.5). Top 10 proteins including S100A14, PKHD1L1, FABP4, ITIH2, C3, C8G, C2, ATF6, ANGPTL6, F13B were performed ELISA to verify. The results showed that PKHD1L1, ANGPTL6, FABP4 and C3 were statistically significant (P<0.05). We performed multivariate logistic regression analysis and plotted a nomogram. Receiver operating characteristic (ROC) curve indicted that the diagnostic efficiency of combined indicators is satisfactory (Aare under curve, AUC=0.835). Furthermore, the prognostic value of the urine proteomics was explored through the intersection between urine proteomics and TCGA RNA-seq data. Thus, COX regression analysis showed that VSIG4, HLA-DRA, SERPINF1, and IGLV2-23 were statistically significant (P<0.05).Conclusion:Our study indicated that the application of urine proteomics to explore diagnostic biomarkers and to construct prognostic models of renal clear cell carcinoma is of certain clinical value. PKHD1L1, ANGPTL6, FABP4 and C3 can assist to diagnose ccRCC. The prognostic model constituted of VSIG4, HLA-DRA, SERPINF1, and IGLV2-23 can significantly predict the prognosis of ccRCC patients, but this still needs more clinical trials to verify.

[Proteomic analysis in combination with CT diagnosis to distinguish renal cell carcinoma from renal benign masses]

Application of SELDI-TOF-MS to identify serum biomarkers for renal cell carcinoma.

[Use of Laser Capture Microdissection and Surface-Enhanced Laser Desorption Ionization Time-of-flight Mass Spectrometry to Screen Differential Proteins in Lung Adenocarcinoma and Lung Squamous Carcinoma].

[Screening for the Serum Differential Proteins of Renal Cell Carcinoma Using Magnetic Beads-Based Matrix-Assisted Laser Desorption/ionization Time-of-flight Mass Spectrometry].

Screening urine markers of renal cell carcinoma using SELDI-TOF-MS]

Two-dimensional gel electrophoresis in screen and identification of differentially expressed proteins between patients with small renal cell carcinoma and healthy controls

Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma

Tree Analysis Pattern of Mass Spectral Urine Profiles in Differential Diagnosis of Bladder Transitional Cell Carcinoma

Quantitative Measurement on Contrast-Enhanced CT Distinguishes Small Clear Cell Renal Cell Carcinoma From Benign Renal Tumors: A Multicenter Study

Diagnosis of pancreatic adenocarcinoma using protein chip technology.

Serum Protein Profiling to Identify Biomarkers for Small Renal Cell Carcinoma.

Tree Analysis of Mass Spectral Urine Profiles Discriminates Transitional Cell Carcinoma of the Bladder from Noncancer Patient

iTRAQ-based quantitative proteomic analysis reveals potential early diagnostic markers of clear-cell Renal cell carcinoma.

Application of Computed Tomography Scanning Parameters Combined with Serum Cripto-1 in the Diagnosis of Renal Cell Carcinoma

Using Tree Analysis Pattern and SELDI-TOF-MS to Discriminate Transitional Cell Carcinoma of the Bladder Cancer from Noncancer Patients

Preoperatively Molecular Staging with CM10 ProteinChip and SELDI-TOF-MS for Colorectal Cancer Patients

CT−based radiomics signature for differentiating pyelocaliceal upper urinary tract urothelial carcinoma from infiltrative renal cell carcinoma

Study of Distinct Protein Profiles for Early Diagnosis of NSCLC Using LCM and SELDI-TOF-MS

Construction of protein profiling models for diagnosis of pancreatic carcinoma

Excavation of Diagnostic Biomarkers and Construction of Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Urine Proteomics.

Whole-Lesion CT Texture Analysis as a Quantitative Biomarker for the Identification of Homogeneous Renal Tumors